{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:13:52Z","timestamp":1791756832625,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Healthy Longevity"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.lanhl.2026.100870","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:20:27Z","timestamp":1784546427000},"page":"100870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of high-dose versus standard-dose influenza vaccines on hospitalisation outcomes and mortality in older adults: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"7","author":[{"given":"Wenshuo","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongna","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengwen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuzhong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9280-4457","authenticated-orcid":false,"given":"Ya","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanhl.2026.100870_bib1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(22)00982-5","article-title":"Influenza","volume":"400","author":"Uyeki","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.lanhl.2026.100870_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0001294","article-title":"Influenza-associated hospitalisation and mortality rates among global Indigenous populations; a systematic review and meta-analysis","volume":"3","author":"Betts","year":"2023","journal-title":"PLoS Glob Public Health"},{"key":"10.1016\/j.lanhl.2026.100870_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2807\/1560-7917.ES.2018.23.16.17-00454","article-title":"Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013","volume":"23","author":"Cassini","year":"2018","journal-title":"Euro Surveill"},{"key":"10.1016\/j.lanhl.2026.100870_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0531-5565(01)00210-8","article-title":"Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly","volume":"37","author":"Murasko","year":"2002","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.lanhl.2026.100870_bib7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanhl.2026.100870_bib9","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/j.vaccine.2017.03.092","article-title":"Efficacy and safety of high-dose influenza vaccine in elderly adults: a systematic review and meta-analysis","volume":"35","author":"Wilkinson","year":"2017","journal-title":"Vaccine"},{"issue":"suppl 1","key":"10.1016\/j.lanhl.2026.100870_bib10","doi-asserted-by":"crossref","first-page":"A24","DOI":"10.1016\/j.vaccine.2020.09.004","article-title":"Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: an updated systematic review and meta-analysis","volume":"39","author":"Lee","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.lanhl.2026.100870_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2023.100327","article-title":"High-dose influenza vaccine in older adults by age and seasonal characteristics: systematic review and meta-analysis update","volume":"14","author":"Lee","year":"2023","journal-title":"Vaccine X"},{"key":"10.1016\/j.lanhl.2026.100870_bib12","article-title":"The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: a meta-analysis of evidence from randomized trials","volume":"89","author":"Skaarup","year":"2024","journal-title":"J Infect"},{"key":"10.1016\/j.lanhl.2026.100870_bib13","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMoa2509907","article-title":"High-dose influenza vaccine effectiveness against hospitalization in older adults","volume":"393","author":"Johansen","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanhl.2026.100870_bib14","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1056\/NEJMoa2509834","article-title":"High-dose influenza vaccine to reduce hospitalizations","volume":"393","author":"Pardo-Seco","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanhl.2026.100870_bib15","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/S0140-6736(25)01742-8","article-title":"Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis","volume":"406","author":"Johansen","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.lanhl.2026.100870_bib16","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.lanhl.2026.100870_bib17","first-page":"1241","article-title":"Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) --- United States, May-June 2009","volume":"58","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.lanhl.2026.100870_bib19","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMoa0906453","article-title":"Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus","volume":"361","author":"Hancock","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanhl.2026.100870_bib20","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.lanhl.2026.100870_bib22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/ije\/28.2.319","article-title":"Simple sample size calculation for cluster-randomized trials","volume":"28","author":"Hayes","year":"1999","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.lanhl.2026.100870_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.lanhl.2026.100870_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12874-018-0618-3","article-title":"Likelihood-based random-effects meta-analysis with few studies: empirical and simulation studies","volume":"19","author":"Seide","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.lanhl.2026.100870_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2288-7-5","article-title":"Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data","volume":"7","author":"Friedrich","year":"2007","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.lanhl.2026.100870_bib26","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.lanhl.2026.100870_bib27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.lanhl.2026.100870_bib28","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.lanhl.2026.100870_bib29","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.lanhl.2026.100870_bib30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"Rating the quality of evidence--study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.lanhl.2026.100870_bib31","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"Rating the quality of evidence--imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.lanhl.2026.100870_bib32","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"Rating the quality of evidence--indirectness","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.lanhl.2026.100870_bib33","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"Rating the quality of evidence--inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.lanhl.2026.100870_bib34","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"Rating the quality of evidence--publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.lanhl.2026.100870_bib35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2021.03.026","article-title":"GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings","volume":"137","author":"Zeng","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.lanhl.2026.100870_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2015.12.007","article-title":"Improving GRADE evidence tables part 1: a randomized trial shows improved understanding of content in summary of findings tables with a new format","volume":"74","author":"Carrasco-Labra","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.lanhl.2026.100870_bib37","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.lanhl.2026.100870_bib38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1086\/599790","article-title":"Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older","volume":"200","author":"Falsey","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lanhl.2026.100870_bib39","author":"Sanofi Pasteur"},{"key":"10.1016\/j.lanhl.2026.100870_bib40","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.vaccine.2013.09.074","article-title":"Immunogenicity and safety of Fluzone\u00ae intradermal and high-dose influenza vaccines in older adults \u226565 years of age: a randomized, controlled, phase II trial","volume":"32","author":"Tsang","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.lanhl.2026.100870_bib41","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1016\/j.vaccine.2015.07.006","article-title":"Prevention of serious events in adults 65 years of age or older: a comparison between high-dose and standard-dose inactivated influenza vaccines","volume":"33","author":"DiazGranados","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.lanhl.2026.100870_bib42","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1093\/infdis\/jiu622","article-title":"Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities","volume":"211","author":"Nace","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lanhl.2026.100870_bib43","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/21645515.2017.1398872","article-title":"Feasibility of a cluster-randomized influenza vaccination trial in U.S. nursing homes: lessons learned","volume":"14","author":"Gravenstein","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.lanhl.2026.100870_bib44","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(17)30235-7","article-title":"Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial","volume":"5","author":"Gravenstein","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lanhl.2026.100870_bib45","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1080\/21645515.2019.1677437","article-title":"Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults \u226565 years of age: a randomized controlled clinical trial","volume":"16","author":"Sanchez","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.lanhl.2026.100870_bib46","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/cid\/ciz1034","article-title":"Comparative immunogenicity of several enhanced influenza vaccine options for older adults: A randomized, controlled trial","volume":"71","author":"Cowling","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanhl.2026.100870_bib47","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1016\/j.vaccine.2022.09.078","article-title":"Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: a phase III, randomized, multi-center study","volume":"40","author":"Chen","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.lanhl.2026.100870_bib48","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200206","article-title":"A pragmatic randomized feasibility trial of influenza vaccines","volume":"2","author":"Johansen","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.lanhl.2026.100870_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13270","article-title":"High-dose quadrivalent influenza vaccine for prevention of cardiovascular and respiratory hospitalizations in older adults","volume":"18","author":"Palmu","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.lanhl.2026.100870_bib50","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s12325-023-02432-1","article-title":"High clinical burden of influenza disease in adults aged \u2265 65 years: can we do better? A systematic literature review","volume":"40","author":"Langer","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.lanhl.2026.100870_bib51","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.2105\/AJPH.2013.301519","article-title":"Influenza and seasonal patterns of hospital use by older adults in long-term care and community settings in Ontario, Canada","volume":"104","author":"Gruneir","year":"2014","journal-title":"Am J Public Health"},{"key":"10.1016\/j.lanhl.2026.100870_bib52","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jinf.2017.09.010","article-title":"Effectiveness of influenza vaccines in preventing severe influenza illness among adults: a systematic review and meta-analysis of test-negative design case-control studies","volume":"75","author":"Rondy","year":"2017","journal-title":"J Infect"},{"key":"10.1016\/j.lanhl.2026.100870_bib53","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1080\/21645515.2017.1344375","article-title":"Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older","volume":"13","author":"Greenberg","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.lanhl.2026.100870_bib54","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1016\/j.vaccine.2019.08.016","article-title":"Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults \u226565 years of age: a phase 3 randomized clinical trial","volume":"37","author":"Chang","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.lanhl.2026.100870_bib55","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/sim.3511","article-title":"Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells","volume":"28","author":"R\u00fccker","year":"2009","journal-title":"Stat Med"}],"container-title":["The Lancet Healthy Longevity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666756826000541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666756826000541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:12:44Z","timestamp":1784934764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666756826000541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2666756826000541"],"URL":"https:\/\/doi.org\/10.1016\/j.lanhl.2026.100870","relation":{},"ISSN":["2666-7568"],"issn-type":[{"value":"2666-7568","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of high-dose versus standard-dose influenza vaccines on hospitalisation outcomes and mortality in older adults: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"The Lancet Healthy Longevity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanhl.2026.100870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lanhl.2026.100886","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100870"}}